CurrentBlue Cross Blue Shield - KansasPolicy N/A

Genotype-Guided Tamoxifen Treatment

This policy addresses use of CYP2D6 genotyping to guide tamoxifen selection or dosing for individuals treated with or at high risk for breast cancer; it applies to Blue Cross and Blue Shield of Kansas members. It summarizes evidence, regulatory status, clinical context, and the payer coverage stance.

Policy Summary

PayerBlue Cross Blue Shield - Kansas

PolicyGenotype-Guided Tamoxifen Treatment

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 12, 2023

Next Review DateN/A

Key ActionVerify member benefits and consider state/federal mandates and member contract language before determining coverage applicability.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

CYP2D6gene discussed

7-10%PM prevalence

Not recommendedNCCN stance

2023-09-12Effective

Coverage Criteria and Policy Position

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered — experimental/investigational

Genotyping coverage: Genotyping to determine CYP2D6 variants is considered experimental/investigational for the purpose of managing tamoxifen treatment in individuals at high risk for or with breast cancer.

Verify member contract benefits for any exceptions.

Evidence base

Evidence synthesis and guideline positions relevant to coverage decisions

Evidence summary: Randomized trial evidence for genotype-directed tamoxifen strategies is limited. The TARGET-1 randomized trial had design and power limitations and did not demonstrate clear clinical benefit for genotype‑guided dosing; no other randomized trials of genotype‑directed drug or strategy choice were identified. Observational and prospective cohort studies have reported mixed results: several large trial subsets (ATAC, BIG 1-98) found no statistically significant association between CYP2D6 phenotype and recurrence, whereas some case-control and cohort analyses reported higher recurrence among CYP2D6 poor metabolizers. A recent single-center prospective cohort (Blancas et al. 2023) assigned tamoxifen dosing by metabolizer status (including dose escalation for PMs) but included few PMs (≤10% of cohort) and may have been underpowered to detect outcome differences.

See individual study summaries (TARGET-1, ATAC, BIG 1-98, Blancas 2023) for details.

Guidelines

Clinical practice guideline statements

Guideline consensus: Guideline statements vary: ASCO (2016) advised against using CYP2D6 polymorphisms to guide adjuvant endocrine therapy (recommendation archived in a 2022 update); CPIC (2018) provided genotype-to-phenotype therapeutic recommendations for tamoxifen with moderate evidence regarding higher recurrence risk in CYP2D6 poor metabolizers; and NCCN (v.4.2023) states that CYP2D6 genotype testing is not recommended for patients considering tamoxifen.

Guideline recommendations differ in detail; NCCN currently recommends against routine testing.

Coverage stance and guidance

Summary of coverage stance and linked guidance

Guideline and policy statements: NCCN (v.4.2023) states CYP2D6 genotype testing is not recommended for patients considering tamoxifen. Blue Cross and Blue Shield of Kansas considers CYP2D6 genotyping to guide tamoxifen management experimental/investigational and not routinely covered; member contract language and state/federal mandates take precedence.

Providers should verify member benefits and consult cited guidelines and policy history.

State and federal mandates and a member's contract language take precedence over this Medical Policy and must be considered first when determining coverage for CYP2D6 genotyping or any related services. To verify a member's specific benefits and any applicable exceptions, contact Blue Cross and Blue Shield of Kansas Customer Service.

The randomized controlled trial TARGET-1 had limited generalizability because it was conducted in a single country with a relatively small sample size and short median follow-up (<10 years; median follow-up reported as < 23 months). The trial did not demonstrate a statistically significant improvement in progression-free survival (PFS) with genotype-guided dosing, despite showing differences in tamoxifen metabolite concentrations between dose and allele groups.

There is no randomized-trial evidence showing that routine CYP2D6 genotype–directed changes in tamoxifen therapy (drug choice, dose escalation, or strategy changes) improve clinical outcomes. The policy review identified no trials examining genotype-directed drug or strategy choice; absence of such evidence is a primary reason routine genotype-directed management is not supported.

Inclusion of procedure, diagnosis, or device codes in this document is for informational purposes only and does not constitute or imply coverage or provider reimbursement. Medical necessity and coverage are determined by the clinical criteria in this policy and the member's contract benefits in effect at the time of service.

Genotyping to determine CYP2D6 variants for the purpose of managing tamoxifen therapy is considered experimental/investigational and is not medically necessary under this Medical Policy for individuals at high risk for or with breast cancer. Refer to the member's contract for any coverage exceptions.

In TARGET-1 (Tamura et al. 2020), genotype-guided higher dosing produced expected differences in tamoxifen metabolite concentrations between dosing and allelic groups but did not result in a significant improvement in progression-free survival (PFS). Reported PFS outcomes showed non-significant hazard ratios and no clear clinical benefit; the trial was a phase II, proof-of-concept design with limited follow-up (median reported as 22.9 months).

National guideline and large-trial evidence do not support routine CYP2D6 testing to guide tamoxifen. The NCCN (v.4.2023) explicitly states CYP2D6 genotype testing is not recommended before prescribing tamoxifen, and subsets from large trials (e.g., ATAC and BIG 1-98) did not show statistically significant associations between CYP2D6 metabolizer phenotype and recurrence.

The National Comprehensive Cancer Network breast cancer guidelines (v.4.2023) state: "CYP2D6 genotype testing is not recommended for patients considering tamoxifen." This guidance supports withholding routine pre-treatment CYP2D6 testing in clinical practice for tamoxifen selection.

Coding and Billing

Documentation Required

Coding and Billing

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member. The code(s) listed below are medically necessary ONLY if the procedure is performed according to the Policy section of this document.

Coverage is contingent on the member's contract and provider agreement with Blue Cross and Blue Shield of Kansas.
Genotype-guided testing (including CYP2D6 testing) is subject to medical necessity criteria in this policy; codes listed are only appropriate when those criteria are met.
Prior authorization may be required for genotype-guided tamoxifen therapy—verify prior authorization requirements with BCBSKS before ordering.
If there are questions about coverage of this service, contact Blue Cross and Blue Shield of Kansas customer service or your professional/institutional relations representative.
No randomized controlled trials definitively demonstrate improved long-term clinical outcomes from genotype-directed dosing of tamoxifen; available evidence includes prospective cohorts and trial-subset analyses.
Some prospective cohorts assigned tamoxifen dose or therapy based on genotype, and other studies reported analyses on trial-subsets rather than primary randomized comparisons.
Providers should document the clinical indication, genotype results, and how the results guided therapy decisions in the medical record to support medical necessity and potential audit requests.
Outcome documentation should include baseline clinical status, genotype result interpretation (e.g., metabolizer status), therapeutic decision made, and clinical follow-up.
If there are questions about coverage of a specific code or test, contact Blue Cross and Blue Shield of Kansas customer service or your professional/institutional relations representative.

Representative CPT/PLA codes (informational)mixed

81226	CYP2D6 gene analysis, common variants
0070U	CYP2D6 common and select rare variants (Mayo Clinic)
0071U	CYP2D6 full gene sequencing (Mayo Clinic)
0072U	CYP2D6 targeted sequence analysis (CYP2D6-2D7 hybrid) (Mayo Clinic)
0073U	CYP2D6 targeted sequence analysis (CYP2D7-2D6 hybrid) (Mayo Clinic)
0074U	CYP2D6 trans-duplication/multiplication non-duplicated gene targeted analysis (Mayo Clinic)
0075U	CYP2D6 5' gene duplication/multiplication targeted sequence analysis (Mayo Clinic)
0076U	CYP2D6 3' gene duplication/multiplication targeted sequence analysis (Mayo Clinic)

Additional PLA codes (informational)mixed

0072U	CYP2D6-2D7 hybrid targeted sequence analysis
0073U	CYP2D7-2D6 hybrid targeted sequence analysis
0074U	Trans-duplication/multiplication non-duplicated gene targeted analysis
0075U	5' gene duplication/multiplication targeted sequence analysis
0076U	3' gene duplication/multiplication targeted sequence analysis

What Providers Should Do

Prior Authorization

Coverage contingent on member contract

Verify the member's contract benefits and applicable state or federal mandates before ordering testing or expecting coverage, as contract language takes precedence over this Medical Policy.

Note

Genotype-guided tamoxifen testing

The intervention considered is CYP2D6 genotype-guided tamoxifen treatment; commercial CYP2D6 single-gene and panel tests are available and referenced in the policy.

Prior Authorization

Prior authorization — include supporting evidence

When requesting coverage for genotype-guided modifications to tamoxifen therapy, include supporting trial or cohort evidence demonstrating clinical benefit, since randomized evidence is lacking and observational findings are mixed.

Billing Rule

Coding applicability (informational)

Procedure and PLA/CPT codes included in the coding section are provided for informational use; medical necessity for those codes depends on meeting the policy's clinical criteria and member contract.

Note

Contact BCBSKS for coverage questions

For questions about coverage or prior authorization specifics, contact Blue Cross and Blue Shield of Kansas Customer Service; the policy does not provide detailed prior authorization instructions.

Step Therapy

Comparative practice — no mandated step therapy

The policy compares genotype-guided tamoxifen strategies with clinically guided tamoxifen but does not impose step-therapy sequencing or require prior failure of clinically guided treatment.

Note

Comparator: clinically guided tamoxifen

The comparator in studies and in current clinical practice is clinically guided tamoxifen treatment (standard clinical decision-making without routine CYP2D6 genotyping).

Documentation Required

Document cohort-based genotype dosing (e.g., Blancas 2023)

Some prospective cohorts (for example, Blancas et al. 2023) assigned tamoxifen dosing by CYP2D6 metabolizer status; when submitting claims or prior authorization requests, document the cohort-based dosing approach and relevant genotype and metabolizer classification.

Blancas et al. (2023) assigned PM, IM, NM, UM status and adjusted PM dosing (example dosing schedule described in study).
Document metabolizer classification and the dosing algorithm applied.

Note

Policy informational — verify coverage

Placeholder informational/provider-action — follow standard policy guidance and verify member-specific coverage prior to ordering services.

Documentation Required

Policy informational — documentation check

Placeholder informational/provider-action — ensure all documentation aligns with the policy's stated clinical criteria and member contract before billing.

Documentation Required

Verify member benefits before ordering testing

Verify member benefits and any applicable mandates with Blue Cross and Blue Shield of Kansas Customer Service before ordering CYP2D6 testing or modifying tamoxifen therapy.

Documentation Required

Document outcomes: therapy changes or ovarian ablation

When genotype-guided management is used, document medication-use outcomes such as a switch to an aromatase inhibitor or use of ovarian ablation in premenopausal women.

Record any change to alternative endocrine therapy (e.g., aromatase inhibitor).
Document use of ovarian ablation when applicable.

Documentation Required

Provide prospective cohort/trial-subset study details with evidence

When submitting genotype-guided tamoxifen claims or prior authorization materials, include prospective cohort or trial-subset details (study name, dates, participant counts, genotyping methods, and metabolizer classification) that support the requested intervention.

Include study identifiers and sample sizes when citing external evidence.
Describe genotyping method and metabolizer classification used in the cited study.

Note

Coverage questions — contact BCBSKS

For coverage questions or to discuss this policy, contact Blue Cross and Blue Shield of Kansas Customer Service or your professional/institutional relations representative.

Denial Risk

Experimental / Investigational — not covered

CYP2D6 genotyping to guide tamoxifen management is considered experimental/investigational under this policy; services labeled experimental/investigational are not covered and may be denied.

Note

No review scheduled — contact for coverage questions

No review or update is scheduled for this Medical Policy; for coverage inquiries or to request reconsideration, contact Blue Cross and Blue Shield of Kansas Customer Service.

Denial Risk

Absence of trial evidence — denial risk

The evidence review identified no trials examining genotype-directed selection of drug or strategy that demonstrated net clinical benefit; this absence of evidence may lead to denial of coverage for genotype-directed tamoxifen interventions.

Note

Policy status — no review scheduled

No review or update is currently scheduled on this policy; contact Blue Cross and Blue Shield of Kansas Customer Service or professional/institutional relations for questions about current coverage.

Clinical Background

Tamoxifen is a prodrug metabolized to active metabolites, notably endoxifen, with formation largely mediated by the hepatic enzyme CYP2D6. CYP2D6 genotype determines metabolizer phenotype categories (poor, intermediate, normal/extensive, ultra-rapid) that influence predicted endoxifen exposure. Additionally, concomitant use of potent CYP2D6 inhibitors (for example, selective serotonin reuptake inhibitors such as fluoxetine or paroxetine) can phenoconvert patients toward a poor metabolizer phenotype and reduce endoxifen concentrations, which is the rationale for considering genotype or drug–drug interaction data when evaluating tamoxifen management strategies.

Definitions and Key Terms

Endoxifen definition — primary active metabolite and role

DefinitionEndoxifen is the primary active metabolite of tamoxifen (4-hydroxy-N-desmethyltamoxifen) and is thought to be the major metabolite that mediates tamoxifen's pharmacodynamic effects.

FormationEndoxifen is formed predominantly by the cytochrome P450 2D6 (CYP2D6) enzyme from tamoxifen metabolism.

Clinical relevanceInter-individual variability in CYP2D6 activity leads to wide variation in plasma endoxifen concentrations, which has been hypothesized to influence tamoxifen treatment response.

CYP2D6 phenotypes — metabolizer category definitions derived from genotype

Ultra-rapid metabolizer (UM)Genotypes with ≥3 functional copies of CYP2D6; phenotype = ultra-rapid metabolizer.

Normal/extensive metabolizer (NM)Genotypes with two functional (normal) alleles; phenotype often labeled normal or extensive metabolizer.

Intermediate metabolizer (IM)Genotypes with one active and one inactive allele, two decreased-activity alleles, or one decreased and one inactive allele; phenotype = intermediate metabolizer.

Poor metabolizer (PM)Genotypes with two inactive (null) alleles; phenotype = poor metabolizer.

Genotype group notation (wt/wt, wt/V, V/V)

wt/wtNotation indicating wild-type allele on both copies (wild type / wild type).

wt/VNotation indicating one wild-type allele and one variant allele (wild type / variant).

V/VNotation indicating variant allele on both copies (variant / variant).

CYP2D6 poor metabolizer — definition

DefinitionA CYP2D6 poor metabolizer is an individual whose genotype includes two inactive (null) CYP2D6 alleles, resulting in markedly reduced or absent CYP2D6 enzyme activity.

Clinical implicationPoor metabolizers may have lower endoxifen concentrations and have been associated in some analyses with increased risk of breast cancer relapse when treated with tamoxifen.

Prevalence in trialsTARGET-1 included only one patient classified as a poor metabolizer with two null alleles, indicating low representation in that RCT.

CYP2D6 metabolizer phenotype categories (poor, intermediate, normal/extensive, ultra)

Poor metabolizer (PM)Genotype with two inactive alleles; phenotype = poor metabolizer; associated with reduced CYP2D6 activity.

Intermediate metabolizer (IM)Genotype combinations such as one active + one inactive allele, two decreased-activity alleles, or one decreased + one inactive allele; phenotype = intermediate metabolizer.

Normal/extensive metabolizer (NM)Genotypes with normal functional alleles resulting in normal CYP2D6 activity.

Ultra-rapid metabolizer (UM)Genotypes with ≥3 functional copies of CYP2D6; phenotype = ultra-rapid metabolizer.

CPT 81226 — CYP2D6 gene analysis description (examples of variants)

CPT 81226 descriptionCPT 81226: CYP2D6 gene analysis — gene analysis for common variants (examples listed include *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, etc.).

ScopeRepresents analysis of common CYP2D6 variants relevant to metabolizer phenotype assignment and pharmacogenetic interpretation.

Usage noteListed for informational coding purposes; medical necessity determined by policy clinical criteria and member contract.

PLA codes 0070U–0076U — descriptions for PLA/other CPT codes for CYP2D6 analyses

0070UCYP2D6 gene analysis, common and select rare variants (e.g., multiple star alleles and copy number) — Test name: CYP2D6 Common Variants and Copy Number; Manufacturer: Mayo Clinic.

0071UCYP2D6 full gene sequence — List separately in addition to code for primary procedure (Test name: CYP2D6 Full Gene Sequencing; Manufacturer: Mayo Clinic).

0072U–0076UTargeted sequence analyses for structural/hybrid and duplication/multiplication events: 0072U (CYP2D6-2D7 hybrid), 0073U (CYP2D7-2D6 hybrid), 0074U (non-duplicated gene when duplication/multiplication is trans), 0075U (5' gene duplication/multiplication), 0076U (3' gene duplication/multiplication).

Intended Purposes and Reported Genotype-Guided Strategies

Genotype-guided therapy purposes

Therapy purposes: Tailor drug selection (tamoxifen vs aromatase inhibitor), dose selection (for example, increasing tamoxifen from 20 mg/day to 40 mg/day), or strategy (such as recommending ovarian ablation in premenopausal women) based on CYP2D6 genotype to minimize treatment failures or toxicities.

Purpose described as rationale for genotype-guided tamoxifen approaches.

Reported genotype-based dosing

Examples of genotype-guided dosing strategies reported

Blancas 2023 dosing: In Blancas et al. (2023) poor metabolizers were assigned an altered dosing regimen: tamoxifen 20 mg/day for 4 months then escalation to 40 mg/day for the subsequent 4 months (with other metabolizer groups receiving standard 20 mg/day); the study noted few PMs and may have been underpowered to detect clinical outcome differences.

Study-specific dosing details are described in the cited cohort report.

Institutional algorithms and endoxifen-based adjustments: Some institutional programs and prospective cohorts modified tamoxifen therapy based on measured low endoxifen (<6 ng/mL) or CYP2D6 status, recommending dose increase or alternative endocrine strategies for patients with low metabolite exposure; these approaches are reported in observational series but lack randomized evidence of outcome benefit.

See Ruddy et al. (2013) and other cohort descriptions for examples of endoxifen‑guided recommendations.

Step Therapy / Dose Adjustment Practices

Program / Study	Example patient counts	Trigger for recommended change	Recommended change (reported)
Ruddy et al (institutional algorithm)	99 patients evaluated; recommendations to modify tamoxifen made for 18 (18%); 2 of those 18 were CYP2D6 poor metabolizers	Low endoxifen concentration (<6 ng/mL)	Recommend modification of tamoxifen therapy (details of specific modifications not reported); changes recommended for 18 of 99 patients

Cohort / Study	CYP2D6 poor metabolizer (PM) count	Dose-escalation approach reported	Evidence summary / Limitations
Blancas et al (2023) — prospective cohort, single center (Spain)	PM, n=13 (of N=220)	PMs: tamoxifen 20 mg/day for 4 months then escalation to 40 mg/day for 4 months (then further regimen described in source)	Reported a protocol assigning dose by metabolizer status; small PM sample (n=13) and single-center design; observational, may be underpowered to detect outcome differences

Prior Authorization

Prior authorization — evidence required for step approaches

When requesting coverage for step approaches (e.g., dose escalation for CYP2D6 poor metabolizers), include supporting trial or cohort evidence demonstrating clinical benefit, as reported step strategies lack randomized evidence.

Document prior standard tamoxifen therapy and rationale for genotype-based dose changes.
Provide cohort or trial data (study name, methods, outcomes) that support the step approach.

Policy Summary

PayerBlue Cross Blue Shield - Kansas

PolicyGenotype-Guided Tamoxifen Treatment

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 12, 2023

Next Review DateN/A

Key ActionVerify member benefits and consider state/federal mandates and member contract language before determining coverage applicability.

SourceLink

On This Page